JNJ halts development of nipocalimab in combination with anti-TNFalpha therapy

The company stated, “The Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients with refractory disease was an innovative approach to test if the combination had the potential to be an effective option in this difficult-to-treat population. At 12 weeks, study results did not show sufficient evidence that the combination therapy provided significant added benefit over anti-TNFalpha therapy alone. Based on these findings, Johnson & Johnson has decided not to proceed with the clinical development of nipocalimab in combination with an anti-TNFalpha therapy for RA. No new safety concerns were found. We are excited to continue the ongoing clinical development program evaluating nipocalimab in potential indications across Rheumatic, Rare Autoantibody and Maternal Fetal diseases. We remain confident in the nipocalimab product having $5B+ potential.”